(Q28207509)

9 April 2017

main subject

prostatic hypertrophy

1 reference

1

Timothy J Wilt

1 reference

9 April 2017

author name string

T J Wilt

1

0 references

A Ishani

2

0 references

I Rutks

3

0 references

R MacDonald

4

0 references

Areef Ishani

2

1 reference

9 April 2017

Indulis Rutks

3

1 reference

9 April 2017

Roderick MacDonald

4

1 reference

9 April 2017

language of work or name

English

0 references

publication date

December 2000

1 reference

9 April 2017

published in

Public Health Nutrition

1 reference

9 April 2017

volume

3

1 reference

9 April 2017

issue

4A

0 references

4a

1 reference

A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia

9 April 2017

page(s)

459-72

0 references

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

Rationale for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

Harmless herbs? A review of the recent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

Phytotherapy in treatment of benign prostatic hyperplasia: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

The value of permixon in benign prostatic hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

Treatment of benign prostatic hyperplasia with phytosterols

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

Inhibitory effect and synergism of cernitin pollen extract on the urethral smooth muscle and diaphragm of the rat

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH.

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

A Clinical and Urodynamic Study of Tadenan in the Treatment of Benign Prostatic Hypertrophy

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

Micturition activity of pollen extract: contractile effects on bladder and inhibitory effects on urethral smooth muscle of mouse and pig

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

Usefulness of Cernilton in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

Saw palmetto for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021

[Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study]

1 reference

https://api.crossref.org/works/10.1017%2FS1368980000000549

7 January 2021